OrthoPediatrics price target lowered to $52 from $59 at BTIG

BTIG analyst Ryan Zimmerman lowered the firm’s price target on OrthoPediatrics to $52 from $59 and keeps a Buy rating on the shares. The firm’s channel checks indicate staffing remains challenged in pediatric hospitals. While staffing challenges have improved, in-patient pediatric procedures continue to be modestly pressured, the analyst tells investors in a research note. The firm sees little change in dynamics from its post-2Q meetings with OrthoPediatrics management. BTIG adds that investor interest in OrthoPediatrics has picked up given that shares are currently trading at their lowest level since the initial public offering.